Dapagliflozin Effect on FunctiOnal Mitral Regurgitation and Myocardial Remodeling (DEFORM)
Functional Mitral Regurgitation
About this trial
This is an interventional treatment trial for Functional Mitral Regurgitation
Eligibility Criteria
Inclusion Criteria: Patients aged >18 years and <90 years LVEF<60% and EROA of mitral regurgitation≥0.2cm2 on echocardiography The structure of mitral valve leaf and chordae tendineae is normal Patients have received GDMT for FMR including a stable, optimized dose of β-blocker and RAAS inhibitors for at least 2 weeks Exclusion Criteria: Allergic to dapagliflozin, or angioedema Already taking dapagliflozin or other SGLT2 inhibitors Presence of primary structural damage to the mitral valve, such as rheumatic heart disease, mitral valve prolapses Non-dialysis chronic kidney disease (CKD) patients with eGFR <30ml/min/1.73m2 or dialysis patients Acute myocardial infarction and acute myocarditis occurred within 3 months Revascularization procedure, CRT, TMVR, surgical valve repair or replacement were performed or planed 3 months before or after enrollment Combining significant aortic valve diseases (moderate or severe regurgitation or stenosis) Combining hyperthyroidism while thyroid function has not returned to normal Pregnant or lactation women
Sites / Locations
- The Third Affiliated Hospital of Sun Yat-Sen UniversityRecruiting
- The First Affiliated Hospital of Sun Yat-Sen UniversityRecruiting
- The Third Affiliated Hospital of Sun Yat-sen University Yuedong HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
dapagliflozin group
control group
GDMT and dapagliflozin 10mg once daily
GDMT only